385 related articles for article (PubMed ID: 35658874)
21. Splicing factor proline- and glutamine-rich regulates cytotoxic T lymphocytes-mediated cytotoxicity on non-small cell lung cancer by directly binding to PD-L1 3'UTR.
Pan Y; Cheng Y
Medicine (Baltimore); 2023 Nov; 102(45):e35837. PubMed ID: 37960731
[TBL] [Abstract][Full Text] [Related]
22. Estradiol initiates the immune escape of non-small cell lung cancer cells via ERβ/SIRT1/FOXO3a/PD-L1 axis.
Song S; Tang H; Quan W; Shang A; Ling C
Int Immunopharmacol; 2022 Jun; 107():108629. PubMed ID: 35344811
[TBL] [Abstract][Full Text] [Related]
23. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer.
Qiao X; Zhao F
Bioengineered; 2022 Apr; 13(4):9264-9273. PubMed ID: 35411833
[TBL] [Abstract][Full Text] [Related]
25. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
[TBL] [Abstract][Full Text] [Related]
26. SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis.
Du Z; Niu S; Wang J; Wu J; Li S; Yi X
Autoimmunity; 2021 Jun; 54(4):225-233. PubMed ID: 33904361
[TBL] [Abstract][Full Text] [Related]
27. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
28. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
29. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
30. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy.
Xiong W; Gao X; Zhang T; Jiang B; Hu MM; Bu X; Gao Y; Zhang LZ; Xiao BL; He C; Sun Y; Li H; Shi J; Xiao X; Xiang B; Xie C; Chen G; Zhang H; Wei W; Freeman GJ; Shu HB; Wang H; Zhang J
Nat Commun; 2022 Mar; 13(1):1700. PubMed ID: 35361799
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG
Man RCH; Qiu Y; Leung SWS; Fruhwirth GO; Lam JKW
Eur J Pharm Biopharm; 2024 Feb; 195():114177. PubMed ID: 38185193
[TBL] [Abstract][Full Text] [Related]
32. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
33. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
34. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.
Pan X; Zhang W; Wang L; Guo H; Zheng M; Wu H; Weng Q; He Q; Ding L; Yang B
Mol Oncol; 2023 Dec; 17(12):2659-2674. PubMed ID: 37606530
[TBL] [Abstract][Full Text] [Related]
35. KCNQ1OT1 sponges miR-34a to promote malignant progression of malignant melanoma via upregulation of the STAT3/PD-L1 axis.
Wang X; Ren Z; Xu Y; Gao X; Huang H; Zhu F
Environ Toxicol; 2023 Feb; 38(2):368-380. PubMed ID: 36399467
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages.
Qian M; Ling W; Ruan Z
Aging (Albany NY); 2020 Sep; 12(17):17122-17136. PubMed ID: 32927431
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.
Zhang Y; Huang S; Gong D; Qin Y; Shen Q
Cell Mol Immunol; 2010 Sep; 7(5):389-95. PubMed ID: 20514052
[TBL] [Abstract][Full Text] [Related]
38. USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
Byun S; Lee SY; Lee J; Jeong CH; Farrand L; Lim S; Reddy K; Kim JY; Lee MH; Lee HJ; Bode AM; Won Lee K; Dong Z
Clin Cancer Res; 2013 Jul; 19(14):3894-904. PubMed ID: 23748694
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA FENDRR attenuates the stemness of non-small cell lung cancer cells via decreasing multidrug resistance gene 1 (MDR1) expression through competitively binding with RNA binding protein HuR.
Gong F; Dong D; Zhang T; Xu W
Eur J Pharmacol; 2019 Jun; 853():345-352. PubMed ID: 30981768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
